GlassScriptPhysician profile
Adam Linck
NPI 1093026882
$1,854.94
in general payments reported to CMS, 2019-2025
24 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.39 · 2020: $30.24 · 2021: $180 · 2022: $540 · 2023: $464 · 2024: $423 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.04 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.67 | 2021-2024 | |
| Amgen INC. | $240.43 | 2021-2025 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $89.03 | 2021-2022 | |
| Lilly USA, LLC | $84.60 | 2019-2023 | Jardiance |
| Pfizer INC. | $78.79 | 2023-2025 | |
| Novo Nordisk INC | $76.74 | 2020-2025 | Rybelsus, Ozempic |
| Actelion Pharmaceuticals US, INC. | $75.92 | 2023-2025 | Uptravi, Opsumit |
| Exact Sciences Corporation | $72.40 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.47 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $53.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $49.24 | 2023 | Invega Sustenna |
| Abbott Laboratories | $43.07 | 2021-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $35.58 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $33.20 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.58 | 2022-2023 | Xifaxan |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $26.97 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $25.36 | 2022-2025 | Shingrix, Bexsero |
| Novartis Pharmaceuticals Corporation | $18.75 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $16.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.54 | 2025 | Eliquis |
| Ascensia Diabetes Care US INC. | $16.09 | 2024 | |
| Sanofi-Aventis U.S. LLC | $14.84 | 2025 | |
| Axsome Therapeutics, INC. | $14.31 | 2024 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Linck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.